ORA and third party payers

Ontario Rheumatology Association and Private Payers: An update As many of you know, major changes to the reimbursement of biologics via third party payers have been occurring, with many insurance companies providing group […]

Read More…


CRA update to Health Canada’s advisory on concomitant methotrexate and PPIs

The Canadian Rheumatology Association has released an update concerning the recent advisory from Health Canada on the concomitant use of Methotrexate and PPIs. An amended release has been made suggesting that the alert […]

Read More…


Quick facts October 2012

Latest News:     Don’t forget to renew your membership now for 2013. Prices go up November 1st, 2012           1.  Aclasta now available for osteoporosis with limited use code 436. For the treatment of osteoporosis […]

Read More…


Upcoming Rheumatology EMR User Forums

Sign up and attend a Rheumatology EMR user forum! Forums are planned to give users an opportunity to meet and share best practices, as well as discuss additional tools that may be needed. […]

Read More…


Sad news of Dr. Hugh Smythe’s passing

 Sad news of Dr. Hugh Smythe’s passing  on October 14, 2012 was received today. Dr. Smythe was an internationally known rheumatologist based at the University of Toronto who helped to guide the Division […]

Read More…


New Limited Use Code for Zolendronic Acid

436 For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal […]

Read More…